Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a strategic partnership with TARA Mind, working alongside Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The collaboration aims to expand mental health awareness within the veteran community while advancing Helus Pharma’s FDA Breakthrough Therapy-designated HLP003 program.

The partnership leverages the networks of TARA Mind and VETS to enhance veteran engagement in clinical trials. This initiative aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, underscoring the national priority to address mental health challenges among veterans. The PARADIGM program is evaluating HLP003, a proprietary novel serotonergic agonist (NSA) designed to activate serotonin pathways believed to promote neuroplasticity, as an adjunctive treatment for major depressive disorder.

“We are honored to collaborate with TARA Mind and VETS to increase awareness and access to our Phase 3 clinical program for veterans suffering from major depressive disorder,” said a Helus Pharma spokesperson. “This partnership reflects our commitment to addressing the unmet mental health needs of those who have served our country.”

Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical-stage pharmaceutical company focused on developing proprietary NSAs. The company’s pipeline includes HLP003, currently in Phase 3 for major depressive disorder with Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs.

The importance of this partnership lies in its potential to accelerate the development of new treatments for depression, a condition that affects millions of veterans and civilians alike. By engaging the veteran community, Helus Pharma not only seeks to recruit participants but also to destigmatize mental health treatment and raise awareness about available clinical trials. The collaboration with TARA Mind and VETS provides a trusted channel to reach veterans who may benefit from investigational therapies.

For more information about Helus Pharma and its programs, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. The full press release is available at https://ibn.fm/o9dCH.

This development highlights the ongoing efforts to address serious mental illness through innovative therapies and collaborative partnerships, marking a step forward in the quest for effective treatments for major depressive disorder.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans.

The post Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans appeared first on citybuzz.